Tax Reform in This Election Year: It's Not Likely
Which Credit Card Rewards Does the IRS Care About?
Usually when a company is able to beat analyst estimates for earnings the stock gets rewarded on Wall Street, but that is not the case today for pharmaceutical giant Genentech Inc. (NYSE: DNA). The company reported its third quarter numbers last night, beating estimates by a penny, but the stock is being sold off by traders today, dropping 1.9% in early morning to$75.94 down $1.56.Analysts had been expecting to see the company show earnings of 72 cents a share, and the actual results came in at 73 cents a share for the quarter. This past quarter the company was able to experience a 22 percent earnings jump, so why is the stock lower today?
The main reason why analysts are are beating up the stock today is concern over the company's ability to maintain its current momentum. Analysts are fearing that the company is not going to be able to continue to shine in the light of increased competition and a saturated market place.
Goldman Earnings Sink After Buffett Dividend
Johnson & Johnson's Income Falls 23%
Burberry Shares Leap on Sales Update
